Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Lower Gastrointestinal Cancers : A Systematic Review and Meta-Analysis

Funding Information: This study was supported by the CanTest Collaborative (funded by Cancer Research UK C8640/A23385) of which Fiona M. Walter is Director, Jon Emery is an Associate Director, Mike Messenger is co-investigator, and Natalia Calanzani and Garth Funston are researchers. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Paige Druce, Kristi Milley and Jon Emery are supported by the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4). Mike Messenger is funded by the NIHR Leeds In Vitro Diagnostic Co-operative (UK). No Rapid Service Fee or Open Access fee was received by the journal for the publication of this article. Funding Information: This study was supported by the CanTest Collaborative (funded by Cancer Research UK C8640/A23385) of which Fiona M. Walter is Director, Jon Emery is an Associate Director, Mike Messenger is co-investigator, and Natalia Calanzani and Garth Funston are researchers. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Paige Druce, Kristi Milley and Jon Emery are supported by the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4). Mike Messenger is funded by the NIHR Leeds In Vitro Diagnostic Co-operative (UK). No Rapid Service Fee or Open Access fee was received by the journal for the publication of this article. We thank Veronica Phillips, Assistant Librarian, University of Cambridge Medical Library, and Jim Berryman, Liaison Librarian, Brownless Biomedical Library University of Melbourne for expert input when developing the search strategy. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Mike Messenger has previously held research grants with Roche Diagnostics, Everest Detection Ltd, SomaLogic Inc, Abbott Laboratories, Myriad Genetics, Inivata, Oncimmune, Janssen and Siemens Healthineers and has also received paid consultancy from PinPoint Data Science Ltd and Cepheid Inc in the field of cancer diagnostics. Garth Funston is a current member of the Oncology Editorial Board for Advances in Therapy. Paige Druce, Natalia Calanzani, Claudia Snudden, Kristi Milley, Rachel Boscott, Dawnya Behiyat, Javiera Martinez-Gutierrez, Smiji Saji, Jasmeen Oberoi, Jon Emery and Fiona M Walter have nothing to disclose. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Publisher Copyright: © 2021, The Author(s).Peer reviewedPublisher PD